La Jolla Pharmaceutical Company was granted an Orphan Drug Designation from the FDA for the Investigational Drug Product, LJPC-0118 (artesunate), for the treatment of malaria.   La Jolla plans to file a New Drug Application (NDA) with the FDA in the fourth quarter of 2019 for LJPC-0118. The active pharmaceutical ingredient in LJPC-0118, artesunate, was demonstrated to be superior to quinine in reducing mortality in patients with severe falciparum malaria infection in two randomized, controlled...